Cargando…
Next-Generation Sequencing with Liquid Biopsies from Treatment-Naïve Non-Small Cell Lung Carcinoma Patients
SIMPLE SUMMARY: Screening for genomic alterations in treatment-naïve non-small cell lung carcinoma (NSCLC) is mainly done by tissue biopsy (TB), an invasive approach. However, it may not be possible to obtain a TB, the patient does not consent to it and/or the extracted nucleic acids are of poor qua...
Autor principal: | Hofman, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122958/ https://www.ncbi.nlm.nih.gov/pubmed/33922637 http://dx.doi.org/10.3390/cancers13092049 |
Ejemplares similares
-
The rational application of liquid biopsy based on next‐generation sequencing in advanced non‐small cell lung cancer
por: Zhao, Chenglong, et al.
Publicado: (2022) -
Implementation of Next Generation Sequencing-Based Liquid Biopsy for Clinical Molecular Diagnostics in Non-Small Cell Lung Cancer (NSCLC) Patients
por: Zulato, Elisabetta, et al.
Publicado: (2021) -
Molecular Profiling in Non-Squamous Non-Small Cell Lung Carcinoma: Towards a Switch to Next-Generation Sequencing Reflex Testing
por: Pujol, Nina, et al.
Publicado: (2022) -
Liquid First Is “Solid” in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing
por: Sehayek, Or, et al.
Publicado: (2022) -
Next-generation sequencing in liquid biopsy: cancer screening and early detection
por: Chen, Ming, et al.
Publicado: (2019)